Conferences - Results from #100

APCCC 2021: Do Different Subgroup of Patients Need Different Treatments? October 9, 2021

APCCC 2021: Are There Still Patients Where Treatment with ADT Alone Is Still Appropriate? October 9, 2021

APCCC 2021: PSMA –Based Imaging: Navigating the Pitfalls of the Different Tracers October 9, 2021

APCCC 2021: The Background of PSMA in Prostate Cancer October 9, 2021

APCCC 2021: What Is the Evidence for “Triplet Therapy”? October 9, 2021

APCCC 2021: Somatic Testing – When and What? (Including Mismatch Repair Evaluation) October 9, 2021

APCCC 2021: PSMA PET: For Staging To Improve Clinical Outcomes October 9, 2021

APCCC 2021: Are There Still Patients Where Treatment with ADT Alone Is Appropriate? October 9, 2021

APCCC 2021: Summary of Panel Responses Regarding Tumor Molecular Testing October 9, 2021

APCCC 2021: Do We Need the Second PET (FDG) for Patient Selection? (Including SUV for Selection of PSMA Therapy) October 9, 2021

APCCC 2021: Panel Results from the Metastatic Hormone Sensitive Prostate Cancer Session October 9, 2021

APCCC 2021: Summary of Panel Responses Regarding PSMA in Diagnostics and Therapy October 9, 2021

APCCC 2021: “Triplet Therapy” for Metastatic Hormone-Sensitive Prostate Cancer, (ADT + Docetaxel + Additional Systemic Therapy) October 9, 2021

APCCC 2021: Do Different Subgroup of Patients Need Different Treatments? October 9, 2021

APCCC 2021: What Is the Evidence for “Triplet Therapy” (ADT + Radiation of the Primary + Additional Systemic Therapy)? October 9, 2021

APCCC 2021: “Triplet Therapy” for Metastatic Hormone-Sensitive Prostate Cancer, (ADT + Radiation of the Primary + Additional Systemic Therapy) October 9, 2021

APCCC 2021: Can Molecular Markers Inform Treatment Decision in mHSPC? October 9, 2021

ESMO 2021: SAABR: Single Arm Phase II Study of Abiraterone + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer (mHSPC) September 29, 2021

ESMO 2021: TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Patients with DDR Gene Mutated Metastatic Castration-sensitive Prostate Cancer (mCSPC) September 29, 2021

ESMO 2021: PSMAddition: A Phase III Trial to Compare Treatment with 177Lu-PSMA-617 plus Standard of Care (SOC) Versus SOC Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer September 29, 2021

Page 6 of 429

email news signup